Overview: Hepatitis Delta PCR TestIntroduction: The Hepatitis Delta PCR Test detects hepatitis D virus (HDV) to diagnose co-infection with hepatitis B, causing severe liver damage. Aligned with 2023 AASLD guidelines, it uses PCR for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in virology for patients with hepatitis B and suspected HDV co-infection, which significantly worsens liver prognosis.
Other Names: HDV PCR Assay, Hepatitis D Detection Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: HDV testing began in the 1980s with the discovery of hepatitis D. PCR-based assays improved in the 2000s, enhancing co-infection detection.
Purpose: Diagnoses hepatitis D co-infection, guides treatment, and detects HDV in patients with hepatitis B and severe liver symptoms to prevent complications.
Test Parameters: 1. Hepatitis D Virus
Pretest Condition: No fasting required. Collect whole blood, serum, plasma, or saliva at any time. Report symptoms like jaundice, liver pain, or fatigue, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document jaundice, liver pain, fatigue, or history of hepatitis B. Include current medications, antiviral treatment history, and risk factors (e.g., IV drug use).
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for specialized antiviral therapy.
Procedural Considerations: Uses PCR to detect HDV RNA. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, typically in hepatitis B-positive patients.
Factors Affecting Result Accuracy: Improper sample handling, contamination, or low viral load can affect results. Hepatitis B therapy may suppress HDV detection.
Clinical Significance: Positive HDV RNA confirms co-infection, prompting specialized therapy (e.g., pegylated interferon). Negative results may require repeat testing in suspected cases.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: HBsAg, anti-HDV IgM, or liver function tests to confirm HDV co-infection and assess liver damage.
Test Limitations: False negatives may occur in low viral load or treated patients. Clinical correlation is needed.
References: AASLD Hepatitis D Guidelines, 2023; Hepatology, Rizzetto M, 2022.
